Simcha Weissman

Dr. Simcha Weissman


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 July 2021 in Liver International
Verified
Journal Article
Closed access
PDF file
TMTej I. Mehta
Tej I. Mehta
SWSimcha Weissman
Simcha Weissman
BFBrian M. Fung
Brian M. Fung
JSJohn Sotiriadis
John Sotiriadis
KLKeith D. Lindor
Keith D. Lindor
JTJames H Tabibian
James H Tabibian

8 January 2021 in Journal of Hepato-Biliary-Pancreatic Sciences
Verified
Journal Article
Closed access
PDF file
SSSachit Sharma
Sachit Sharma
SWSimcha Weissman
Simcha Weissman
KAKanana Aburayyan
Kanana Aburayyan
AAAshu Acharya
Ashu Acharya
MAMuhammad Aziz
Muhammad Aziz
SPStephen J. Pandol
Stephen J. Pandol

17 May 2021 in Journal of Crohn's and Colitis
Verified
Journal Article
Closed access
PDF file
SWSimcha Weissman
Simcha Weissman
KPKirtenkumar Patel
Kirtenkumar Patel
SKSindhura Kolli
Sindhura Kolli
MLMegan Lipcsey
Megan Lipcsey
NQNabeel Qureshi
Nabeel Qureshi
JFJoseph Feuerstein
Joseph Feuerstein
Rates of obesity are rising in patients with inflammatory bowel disease. (IBD). We conducted a United States population-based study to determine the effects of obesity on outcomes in hospitalized patients with IBD. We searched the Nationwide Readmissions Database from 2016-2017 to identify all adult patients hospitalized for IBD using ICD-10 codes. We compared obese (BMI ≥30) vs. non-obese (BMI <30) patients with IBD to evaluate the independent effects of obesity on readmission, mortality, and other hospital outcomes. Multivariate regression and propensity matching were performed. We identified 143,190 patients with IBD, of whom 9.1% were obese. Obesity was independently associated with higher all-cause readmission at 30- (18% vs 13% [aOR 1.16, p=0.005]) and 90-days (29% vs 21% [aOR 1.27, p<0.0001]), as compared to non-obese patients, with similar findings upon a propensity matched sensitivity analysis. Obese and non-obese patients had similar risks of mortality on index admission (0.24% vs 0.31%, p=0.18), and readmission (1.5% vs 1.8% p=0.3). Obese patients had longer (5.3 vs 4.9 days) and more expensive ($12,195 vs $11,154) hospitalizations on index admission. Obesity did not affect the risk of intestinal surgery or bowel obstruction. Compared to index admissions, readmissions were characterized by increased mortality (6-fold), healthcare use, and bowel obstruction (3-fold) (all p<0.0001). Obesity in IBD appears to be associated with increased early readmission, characterized by a higher burden, despite the introduction of weight-based therapeutics. Prevention of obesity should be a focus in the treatment of IBD to decrease readmission and healthcare burden.

14 May 2023 in Diseases
Verified
Journal Article
Open access
PDF file
Ayrton Ilolo BangoloAyrton Ilolo Bangolo
Ayrton Ilolo Bangolo
PFPierre Fwelo
Pierre Fwelo
KIKritika M. Iyer
Kritika M. Iyer
SKSarah Klinger
Sarah Klinger
LTLorena Tavares
Lorena Tavares
SWSimcha Weissman
Simcha Weissman
Background: Primary cardiac sarcomas (PCS) are extremely rare malignant tumors involving the heart. Only isolated case reports have been described in the literature over different periods of time. This pathology has been associated with a dismal prognosis and given its rarity; treatment options are very limited. Furthermore, there are contrasting data about the effectiveness of current treatment modalities in improving the survival of patients with PCS, including surgical resection which is the mainstay of therapy. There is a paucity of data on the epidemiological characteristics of PCS. This study has the objective of investigating the epidemiologic characteristics, survival outcomes, and independent prognostic factors of PCS. Methods: A total of 362 patients were ultimately registered in our study from the Surveillance, Epidemiology, and End Results (SEER) database. The study period was from 2000 to 2017. Demographics such as clinical characteristics, overall mortality (OM), and PCS-specific mortality (CSM) were taken into account. A p value of <0.1 in the univariate analysis leads to the incorporation of the variable into multivariate analysis adjusting for covariates. Adverse prognostic factors were represented by a Hazard Ratio (HR) greater than one. The five-year survival analysis was carried out using the Kaplan–Meier method and the log-rank test was used to compare survival curves. Results: Crude analysis revealed a high OM in age 80+ (HR = 5.958, 95% CI 3.357–10.575, p < 0.001), followed by age 60–79 (HR = 1.429, 95% CI 1.028–1.986, p = 0.033); and PCS with distant metastases (HR = 1.888, 95% CI 1.389–2.566, p < 0.001). Patients that underwent surgical resection of the primary tumor and patients with malignant fibrous histiocytomas (HR = 0.657, 95% CI 0.455–0.95, p = 0.025) had a better OM (HR = 0.606, 95% CI 0.465–0.791, p < 0.001). The highest cancer-specific mortality was observed in age 80+ (HR = 5.037, 95% CI 2.606–9.736, p < 0.001) and patients with distant metastases (HR = 1.953, 95% CI 1.396–2.733, p < 0.001). Patients with malignant fibrous histiocytomas (HR = 0.572, 95% CI 0.378–0.865, p = 0.008) and those who underwent surgery (HR = 0.581, 95% CI 0.436–0.774, p < 0.001) had a lower CSM. Patients in the age range 80+ (HR = 13.261, 95% CI 5.839–30.119, p < 0.001) and advanced disease with distant metastases (HR = 2.013, 95% CI 1.355–2.99, p = 0.001) were found to have a higher OM in the multivariate analyses adjusting for covariates). Lower OM was found in patients with rhabdomyosarcoma (HR = 0.364, 95% CI 0.154–0.86, p = 0.021) and widowed patients (HR = 0.506, 95% CI 0.263–0.977, p = 0.042). Multivariate cox proportional hazard regression analyses of CSM also revealed higher mortality of the same groups, and lower mortality in patients with Rhabdomyosarcoma. Conclusion: In this United States population-based retrospective cohort study using the SEER database, we found that cardiac rhabdomyosarcoma was associated with the lowest CSM and OM. Furthermore, as expected, age and advanced disease at diagnosis were independent factors predicting poor prognosis. Surgical resection of the primary tumor showed lower CSM and OM in the crude analysis but when adjusted for covariates in the multivariate analysis, it did not significantly impact the overall mortality or the cancer-specific mortality. These findings allow for treating clinicians to recognize patients that should be referred to palliative/hospice care at the time of diagnosis and avoid any surgical interventions as they did not show any differences in mortality. Surgical resection, adjuvant chemotherapy, and/or radiation in patients with poor prognoses should be reserved as palliative measures rather than an attempt to cure the disease.

17 July 2021 in International Journal of Colorectal Disease
Verified
Journal Article
Closed access
SWSimcha Weissman
Simcha Weissman
SGSara Ghoneim
Sara Ghoneim
ASAva Sanayei
Ava Sanayei
HSHyder Said
Hyder Said
SRSamuel Rosenblatt
Samuel Rosenblatt
JFJoseph D. Feuerstein
Joseph D. Feuerstein

1 September 2019 in Translational Gastroenterology and Hepatology
Verified
Journal Article
Open access
PDF file
SWSimcha Weissman
Simcha Weissman
ACAbimbola Chris-Olaiya
Abimbola Chris-Olaiya
TMTej I. Mehta
Tej I. Mehta
MAMuhammad Aziz
Muhammad Aziz
AAAli Alshati
Ali Alshati
MSMichael A. Sciarra
Michael A. Sciarra
Amongst other indications, cyclosporine therapy has emerged as a novel agent for the management of severe refractory ulcerative colitis (UC). In the historic population of patients receiving cyclosporine therapy—namely solid organ transplant patients—renal toxicity has proven to be a significant mitigating side effect limiting the therapeutic window. However, dose-limiting sequelae amongst patients receiving cyclosporine for inflammatory bowel disease (IBD) have not been as significant. As a result, the fear of renal toxicity as an adverse effect is less of a concern in IBD patients. The goal of this manuscript is to emphasize the need for future research to explore optimal drug dosing and extended use of cyclosporine therapy in the treatment of IBD—given its pathophysiology, efficacy, and safety profile in patients with IBD.